ADH-6 |
Catalog No.GC64235 |
ADH-6 es un compuesto de tripiridilamida. ADH-6 anula el autoensamblaje del subdominio de nucleaciÓn de agregaciÓn del mutante p53 DBD. ADH-6 se dirige y disocia agregados de p53 mutantes en células cancerosas humanas, lo que restaura la actividad transcripcional de p53, lo que lleva a la detenciÓn del ciclo celular y la apoptosis. ADH-6 tiene potencial para la investigaciÓn de enfermedades cancerosas.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2227429-65-2
Sample solution is provided at 25 µL, 10mM.
ADH-6 is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53’s transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 has the potential for the research of cancer diseases[1].
[1]. Palanikumar L, et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat Commun. 2021;12(1):3962.
Average Rating: 5
(Based on Reviews and 38 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *